A company has recently announced the national launch of a number of diagnostic cancer tests, which should help to identify different types of cancer, which would subsequently make it easier for more appropriate and effective treatment to be given to patients and for a faster diagnosis to be made.

The announcement was made by Prometheus Laboratories Inc., which has announced the commercial launch of the tests. One of these is to identify pleural mesothelioma, which is a type of asbestos cancer that is linked to exposure to asbestos. This test is called ProOnc Mesothelioma Dx.

The two other cancer diagnostic tests launched by the company are ProOnc TumorSource Dx and ProOnc Squamous Dx. All of the tests are based on MicroRNA technology, which are non-coding, miniscule sequences of RNA that are vital to many pathological and biological processes.

ProOnc Mesothelioma Dx utilizes this technology in order to identify malignant pleural mesothelioma from other types of lung cancers, and it uses MicroRNA technology to differentiate between the different cancers.

Be Sociable, Share!